PDUFA Date
NUVL: FDA Decision: jideytro
July 22, 2026 · jideytro · approval. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- July 22, 2026
- Company
- Nuvalent, Inc. (NUVL)
- Drug
- jideytro
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
PDUFA Dateapproval
FDA Decision: jideytro
- Company
- Nuvalent, Inc. (NUVL)
- Drug
- jideytro
- Indication
- 1 INDICATIONS AND USAGE JIDEYTRO is indicated for the treatment of adult patients with locally advanced or metastatic ROS1 -positive non-small cell lung cancer (NSCLC) who received a prior ROS1 kinase inhibitor [see Dosage and Administration ( 2.1 ), Clinical Studies ( 14.1 )] . JIDEYTRO is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic ROS1 -positive non-small cell lung cancer (NSCLC) who received a prior ROS1 kinase inhibitor.( 1 )